Cell-delivered magnetic nanoparticles caused
hyperthermia-mediated increased survival
in a murine pancreatic cancer model by Basel, Matthew T. et al.
© 2012 Basel et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2012:7 297–306
International Journal of Nanomedicine
Cell-delivered magnetic nanoparticles caused 
hyperthermia-mediated increased survival  
in a murine pancreatic cancer model
Matthew T Basel1
Sivasai Balivada1
Hongwang Wang2
Tej B Shrestha1
Gwi Moon Seo1
Marla Pyle1
Gayani Abayaweera2
Raj Dani2
Olga B Koper2
Masaaki Tamura1
Viktor Chikan2
Stefan H Bossmann2
Deryl L Troyer1
1Department of Anatomy and 
Physiology, College of Veterinary 
Medicine, 2Department of Chemistry, 
Kansas State University,  
Manhattan, KS, USA
Correspondence: Matthew T Basel 
1600 Denison Ave, 228 Coles Hall, 
Kansas State University,  
Manhattan, KS 66506, USA 
Tel +1 785 532 4519 
Email mbasel@vet.ksu.edu
Abstract: Using magnetic nanoparticles to absorb alternating magnetic field energy as a method 
of generating localized hyperthermia has been shown to be a potential cancer treatment. This 
report demonstrates a system that uses tumor homing cells to actively carry iron/iron oxide 
nanoparticles into tumor tissue for alternating magnetic field treatment. Paramagnetic iron/
iron oxide nanoparticles were synthesized and loaded into RAW264.7 cells (mouse monocyte/
macrophage-like cells), which have been shown to be tumor homing cells. A murine model 
of disseminated peritoneal pancreatic cancer was then generated by intraperitoneal injection 
of Pan02 cells. After tumor development, monocyte/macrophage-like cells loaded with iron/
iron oxide nanoparticles were injected intraperitoneally and allowed to migrate into the tumor. 
Three days after injection, mice were exposed to an alternating magnetic field for 20 minutes 
to cause the cell-delivered nanoparticles to generate heat. This treatment regimen was repeated 
three times. A survival study demonstrated that this system can significantly increase survival in 
a murine pancreatic cancer model, with an average post-tumor insertion life expectancy increase 
of 31%. This system has the potential to become a useful method for specifically and actively 
delivering nanoparticles for local hyperthermia treatment of cancer.
Keywords: cytotherapy, pancreatic cancer, disseminated peritoneal carcinomatosis, targeted 
magnetic hyperthermia, nanoparticles
Introduction
Pancreatic cancer is known to be one of the most lethal forms of cancer with 5-year 
survival rates of less than 5%.1 Discovering new methods for successfully treating 
pancreatic cancer is a virtual necessity for combating this disease.
Hyperthermia has been a cancer therapy method for decades. Tumors have been 
shown to have increased susceptibility to elevated temperature compared to healthy 
tissue due to their increased rate of cell cycling, increased hypoxia, poor fluid 
exchange, and increased acidity.2,3 Whole body hyperthermia is used clinically to take 
advantage of this differential toxicity to treat cancer. Unfortunately, “extreme” whole 
body hyperthermia (.41.5°C), which elevates core temperatures to the level where 
direct thermal toxicity is observed, can cause severe side effects, which may limit 
its usefulness.4–8 Fever-level whole body hyperthermia (∼39°C–41°C) can mitigate 
many of these side effects and has potential to be an effective cancer treatment, but 
this lower heat level is thought, primarily, to stimulate the immune system and the 
benefits of direct thermal toxicity are reduced.9,10 Generating localized hyperthermia 
at the cancer site could alleviate many of the side effects associated with whole body 
hyperthermia while still taking advantage of the thermal susceptibility of tumors. 
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One particularly promising method for generating localized 
hyperthermia is using magnetic nanoparticles to absorb 
energy from alternating magnetic f ields (AMF) and 
converting this energy into heat. This method is promising 
because the body is extremely permeable to AMF, which 
itself produces no known effects in the body. For magnetic 
hyperthermia, superparamagnetic iron oxide nanoparticles 
are usually used for absorbing the magnetic field. Core-shell 
iron/iron oxide nanoparticles have advantages over the simple 
iron oxide nanoparticles because the solid iron core gives a 
much stronger magnetization to the nanoparticle, allowing 
the nanoparticle to absorb the AMF more efficiently. Iron/
iron oxide magnetic nanoparticles have also been shown 
to be safe in vivo and can show very low toxicity when 
administered in vivo.11–14 Only at the location of the magnetic 
nanoparticles is AMF energy absorbed and converted to heat. 
By specifically delivering the magnetic nanoparticles to the 
tumor site, localized hyperthermia can be created.15–17 Using 
magnetic nanoparticles for generating localized hyperthermia 
has proven successful,18–28 and there are several clinical trials 
using injectable magnetic nanoparticles combined with AMF 
for tumor treatment. Current methods of delivering magnetic 
nanoparticles for localized hyperthermia depend on direct 
injection of milligram amounts of magnetic nanoparticles 
into the tumor site.18–27 Although practical for easily 
accessible tumors, this direct injection limits the usefulness 
of magnetic nanoparticle-generated localized hyperthermia 
for deep tumors, locally or systemically metastatic tumors, 
and other diffuse tumors.
A recent method for targeting cancer therapy is using 
cytotherapy. Cytotherapy utilizes delivery cells, such as stem 
cells or other cells, to carry a payload into the tumor site.29–37 
Cytotherapy-directed hyperthermia has been successfully 
demonstrated to attenuate mouse melanomas.38
Monocytes and macrophages are known to infiltrate tumor 
sites and thus could act as cytotherapeutic drug delivery 
vehicles.39,40 Several recent studies have demonstrated the 
feasibility of  delivering therapeutics to tumors using monocytes 
or macrophages, including targeting liposomes containing 
fluorescent markers to gastric tumors,41 targeting adenovirus to 
prostate tumors,42 and targeting gold nanoshells to gliomas.43
This report demonstrates a system that uses monocyte-
like tumor homing cells to deliver magnetic nanoparticles 
directly into the tumor tissue. It was demonstrated that 
RAW264.7 cells (monocyte/macrophage-like cells, Mo/Ma, 
ATCC TIB-71) specifically infiltrate pancreatic tumors when 
injected intraperitoneally (i.p.) without infiltrating other 
organs. These cells were loaded with magnetic nanoparticles 
in order to deliver the magnetic nanoparticles specifically to 
the tumors for localized hyperthermia. To test this system, a 
murine model of disseminated peritoneal carcinomatosis of 
the pancreas was generated by injecting Pan02 cells i.p. into 
C57BL/6 mice.44 Magnetic nanoparticle-loaded Mo/Ma were 
then injected and allowed to infiltrate the tumor tissue. Three 
days after Mo/Ma injection, mice were treated with AMF. 
This treatment system significantly increased the survival 
time of mice bearing i.p. pancreatic tumors, with an average 
lifespan increase post-tumor injection of 31%.
Materials and methods
Reagents and cells
C57BL/6 mice (11 weeks old) were purchased from Charles 
River Laboratories (Wilmington, MA). RAW264.7 cells 
were purchased from ATCC (Manassas, VA), authenticated 
by ATCC using cell morphology, karyotype analysis, and 
cytochrome C oxidase analysis, and cultured for less than 
6 months. Pan02 cells were obtained from the Division of 
Cancer Treatment and Diagnosis Tumor Repository (National 
Cancer Institute, Frederick, MD), authenticated by the 
National Cancer Institute using cell morphology, and cultured 
for less than 6 months. Fetal bovine serum, neocuproine, 
ascorbic acid, ammonium acetate, concentrated hydrochloric 
acid, tetrahydrofuran, succinic anhydride, dopamine 
 hydrochloride, di-tert-butyl dicarbonate, 1,2-dichloroethane, 
4- dimethylaminopyridine, trifluoroacetic acid, tetraethylene 
glycol, Hoechst 33258, PKH26, and benzyl bromide were 
purchased from Sigma-Aldrich Corporation (St Louis, MO). 
Roswell Park Memorial Institute (RPMI) medium, Geneticin® 
(G418), hygromycin B, and penicillin-streptomycin were 
purchased from Invitrogen (Carlsbad, CA). Thiazolyl blue and 
sodium dodecyl sulfate were purchased from Thermo Fisher 
 Scientific (Pittsburgh, PA). Ferrozine reagent (FerroZine®) 
was purchased from Hach Company (Loveland, CO).
Cell culture
Double-stable RAW264.7 cells were cultured in RPMI 
medium containing 10% fetal bovine serum, 100 µg/mL 
G418, and 100 µg/mL hygromycin in a 37°C humidified 
incubator with 5% carbon dioxide. Pan02 cells were cultured 
in Roswell Park Memorial Institute with 10% fetal bovine 
serum and 1 × penicillin-streptomycin in a 37°C humidified 
incubator with 5% carbon dioxide.
Synthesis of nanoparticles
The synthesis of iron/iron oxide nanoparticles has been 
reported by direct reduction of iron chloride in aqueous 
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nanodroplets in reverse micelles (cetyltrimethylammonium 
bromide, n-octane, tert-butyl).45–47 In order to obtain much 
better defined conditions, the synthesis of iron oxide nano-
particles was performed prior to its reduction to iron(0) by 
adding defined amounts of ammonia to the reverse micelles 
under an argon atmosphere. Due to the change in pH in the 
nanodroplets (from ,2 to .7), iron oxide nanoparticles were 
formed, which can be harvested by centrifugation (at 10,000 
rpm for 10 minutes), redispersed in ethanol at 0°C, and then 
reduced by adding solid sodium-borohydride. The last step 
consisted of dispersing iron/iron oxide nanoparticles in 
water (argon atmosphere) and spinning off the nanoparticles 
(at 15,000 rpm for 5 minutes). This step was repeated three 
times to remove all the byproducts of the reduction process.48 
After sodium-borohydride reduction, each nanorod contained 
an iron(0) core, as identified by high-resolution transmis-
sion electron microscope (lattice constant: 0.287 nm).49
The ligand 3-(3,4-dihydroxyphenethylcarbamoyl)
propanoic acid tetraethylene glycol ester (ligand 1) was 
synthesized from 3-(3,4-dihydroxyphenethylcarbamoyl)
propanoic acid; 3-(3,4-dihydroxyphenethylcarbamoyl)
propanoic acid was synthesized by multistep protection and 
deprotection of dopamine hydrochloride, followed by react-
ing with succinic anhydride, 1,2-dichloroethane coupling 
with tetraethylene glycol, and palladium on carbon-catalyzed 
hydrogenation deprotecting benzyl group according to pub-
lished methods.50,51 Ligand 1 (40 mg) was dissolved in 5 mL 
tetrahydrofuran, and 20 mg iron/iron oxide nanoparticles 
were added. After sonicating for 60 minutes, the nano-
particles were precipitated by centrifugation (15,000 rpm, 
5 minutes) and washed with 3.0 mL of tetrahydrofuran for 
ten washing-centrifugation/redispersion cycles (Figure 1A). 
After drying in high vacuum, 18 mg of surface-modified 
nanoparticles were obtained. Transmission electron micros-
copy (Philips CM 100, 100kV and FEI Tecnai F20XT, 200kV; 
FEI, Hilsboro, OR) imaging showed that the resulting nano-
particles were rod-like in shape (Figure 1B–D).
Loading Mo/Ma with nanoparticles 
and determination of iron loading 
concentration
To determine the optimal concentration for nanoparticle 
loading, Mo/Ma were plated in 24-well plates and allowed to 
come to 70% confluency. Medium was removed from the cells 
and fresh medium was added containing 0–200 µg/mL iron 
from the nanoparticles. Sixteen hours later the medium was 
removed, the cells were washed with phosphate buffered saline 
(PBS), and fresh medium was added. Loading  confirmation 
and concentration were obtained by lifting the cells and 
running a ferrozine assay for iron content. The  percentage 
of cells loaded was  measured using flow cytometry. Cyto-
toxicity was measured using 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium  bromide (MTT) assay.
For injections, Mo/Ma were cultured to 70% confluency 
in T75 flasks. Sixteen hours before using the cells, cells for 
groups three and five (see below) were given nanoparticles 
containing 373 µg (37.3 µg/mL) of iron added to the media 
in 100 µL of PBS and mixed well. At the same time, cells for 
groups one, two, and four were given 100 µL of PBS. The next 
morning, the medium was removed, the cells were washed 
with PBS, and fresh medium was added. The cells were 
lifted by scraping and counted in a hemocytometer (Fisher 
Scientific, St Louis, MO) using trypan blue. The correct cell 
density was attained by spinning the cells in 15 mL conical 
tubes at 1000 rpm for 5 minutes and resuspending in the 
correct volume of PBS to give 2,000,000 cells in 100 µL.
Ferrozine assay
To determine the iron content of the nanoparticle solutions 
and the nanoparticle-loaded cells, a ferrozine assay for 
iron was carried out. Ferrozine reagent was prepared by 
dissolving 9.7 g ammonium acetate and 8.8 g of ascorbic 
acid in 10 mL of water. Ferrozine (80 mg) and neocuproine 
(80 mg) were added to the solution and water was added 
to bring the total volume to 25 mL. The sample to be mea-
sured (either cell suspension or nanoparticle solution) was 
diluted to appropriate concentrations in deionized water. 
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Figure 1 Nanoparticle synthesis. (A) Core/shell iron/iron oxide nanoparticles were 
synthesized and then coated in a dopamine based stealth ligand. (B–D) Transmission 
electron microscopic image of obtained particles showing bunched rods.
Abbreviations: Fe, iron; Fe3O4, iron oxide; THF, tetrahydrofuran.
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For cell suspension samples, the cells were counted on a 
hemocytometer using trypan blue before dilution. The diluted 
sample (2 mL) was then placed in a test tube and 0.5 mL of 
1.2 M hydrochloric acid and 0.2 mL of 2M ascorbic acid 
were added. The sample was then vortexed and incubated 
at 70°C for 1 hour. The ferrozine reagent (0.2 mL) was then 
added to the test tube and the sample was incubated at room 
temperature for 30 minutes. A standard curve was also pre-
pared with 0, 0.1, 0.2, 0.5, 1, 2, and 5 µg/mL iron and treated 
in the same way. After the second incubation, the absor-
bance at 562 nm of the standard curve and the samples was 
 measured. The absorbance
562 nm
 versus iron concentration was 
plotted for the standard curve and the sample concentration 
was determined.
Flow cytometry
To f ind the percent of magnetic nanoparticle-loaded 
Mo/Ma, cells were treated with nanoparticles containing 
5, 10, 15, 20, or 25 µg/mL iron. The cells were incubated 
overnight, washed twice with 1 × PBS, and analyzed by 
flow cytometry (Guava EasyCyte™ Plus System; Millipore 
Corporation, Billerica, MA). Side scatter was measured and 
used as a marker for nanoparticles; cells with increased side 
scatter compared to control cells were counted as magnetic 
nanoparticle-loaded cells. The experiment was conducted in 
triplicate and 10,000 cells were analyzed for each replicate. 
Data were analyzed by using CytoSoft® software (Cytosoft 
5.3; Guava EasyCyte Plus System; Millipore).
MTT assay
Thiazolyl blue was dissolved in PBS at 5 mg/mL to give 
the reagent solution. MTT buffer solution was prepared as 
10% (weight/volume) sodium dodecyl sulfate and 0.1 M 
hydrochloric acid in water. To assay cell viability, the reagent 
solution was added 1:10 to the cell medium and the cells were 
placed back into the incubator. After 4 hours, the MTT buffer 
solution was added 1:1 to the medium and the plates were 
placed back into the incubator overnight. After incubating, 
the absorbance at 550 nm and 690 nm was recorded. Quantity 
(absorbance
550 nm
 – absorbance
690 nm
) was calculated and the 
control value was scaled to 100% cell viability.
Tumor homing
To test the homing ability of Mo/Ma cells on Pan02 tumors, 
7 × 105 Pan02 cells were injected i.p. to two mice on day 
zero. On day four, 1 × 106 PKH26 red fluorescent dye labeled 
Mo/Ma cells were injected i.p. (manufacturer’s instructions 
were followed for PKH26 labeling). Mice were euthanized 
on day seven and day ten, and tissues (mesentery/tumor, 
kidney, liver, spleen, lung) collected and fixed in buffered 
neutral formalin. Twenty-four hours after fixation, tissues 
were incubated in sucrose gradient and snap frozen. Five to 
eight micron sections were made and stained with Hoechst 
for nuclear counterstaining; serial sections were stained with 
hematoxylin and eosin.
To verify that Mo/Ma cells were within Pan02 tumors, 
7 × 105 Pan02 cells expressing firefly luciferase intracellularly 
were injected i.p. to five mice on day zero. On day 13, 1 × 106 
Hoechst-labeled Mo/Ma cells were loaded with magnetic 
nanoparticles and injected i.p. Mice were euthanized on day 
17 and tissues were snap-frozen. Five to eight micron sections 
were prepared by cryostat sectioning and stained with rabbit 
α-firefly luciferase antibody and DyLight® 650 conjugated 
sheep α-rabbit IgG antibody (Abcam, Cambridge, MA).
Magnetic heating apparatus  
to generate AMF
The AMF was generated by a converted 10 kW commercial 
inductive heater (Superior Induction Company, Pasadena, 
CA). In these experiments, only 1.5 kW power was used to 
produce 145 kHz sinusoidal AMF in a copper coil. (The power 
absorption of magnetic nanoparticles from AMF strongly 
increases with the frequency. This would suggest that higher 
frequency is desirable to produce better effects for magnetic 
hyperthermia treatment. In addition to the absorption of the 
magnetic nanoparticles, the tissue also absorbs energy from 
the magnetic field. This latter effect is also a strong function of 
the frequency. The optimum value of the frequency has been 
found to be around ∼100 kHz).52 The magnetic field intensity 
was calculated to be approximately 0.05 Tesla. The four-turn 
1″ diameter coil was coated with silver and water cooled to 
eliminate residual heating effects from the resistive loss. The 
diameter of the coil was chosen to facilitate the complete 
inclusion of mice in a perforated plastic tube inside the coil.
Intratumoral nanoparticle  
heat generation
Six C57BL/6 mice (11 weeks old) were injected with 
700,000 Pan02 cells in 100 µL PBS subcutaneously. To cre-
ate a model for intratumoral heat generation by the loaded 
Mo/Ma, 21 days later, when tumors were palpable, 1,000,000 
Mo/Ma loaded with nanoparticles were injected in 10 µL 
PBS intratumorally to three of the mice. The other three 
mice received 1,000,000 unloaded Mo/Ma in 10 µL PBS 
intratumorally. After injections, the mice were euthanized 
and the tumors were removed. The temperature of the tumors 
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was recorded using an infrared camera (FLIR, Boston, MA). 
The tumors were then exposed to AMF for 15 minutes and 
the temperature of the tumors was again measured using the 
infrared camera. The difference in temperature before and 
after AMF was calculated and the loaded and unloaded 
monocyte groups were compared.
In vivo experiment
C57BL/6 mice (11 weeks old) were injected with 
700,000 Pan02 cells in 100 µL PBS i.p. on day zero to gener-
ate a murine model of disseminated pancreatic cancer. These 
mice were then randomly divided into five groups as follows: 
(1) tumor control; (2) Mo/Ma control; (3) nanoparticle con-
trol; (4) AMF control; and (5) AMF treatment.
On day five, 2 × 106 Mo/Ma loaded with nanoparticles 
were injected in 100 µL PBS i.p. to groups three (nanoparticle 
control) and five (AMF treatment). Groups two (Mo/Ma 
control) and four (AMF control) also received 2 × 106 
Mo/Ma which were not loaded. Group one (tumor control) 
received 100 µL PBS i.p. This procedure was repeated on 
days nine and 13.
On day eight, mice from groups four (AMF control) and 
five (AMF treatment) were anesthetized with isoflurane and 
exposed to an AMF for 20 minutes. This procedure was 
repeated on days 12 and 16.
After three rounds of treatments, the mice were closely 
observed and allowed to continue until they displayed signs 
of clinical symptoms of cancer, at which point they were 
euthanized using carbon dioxide, and the tumors were 
 collected and weighed (Figure 2).
Duration of clinical symptoms
The measured outcome for this study was mouse survival. To 
minimize potential pain and distress of the mice, however, 
a system was developed that allowed euthanasia of the mice 
shortly before they died. The mice were scored numerically 
one to five based on the body condition of the mice (primarily 
the spine and dorsal pelvic bone prominence) with a score of 
three indicative of a healthy mouse. This initial score was then 
modified by the presence of extreme lethargy,  dehydration, 
ataxia, head tilt, severe hunching, limb  dragging, severe 
raised hair, Harderian gland secretions, ascites, labored 
breathing, or bloody tail. Pronounced symptoms led to a 
subtraction of one point from the body condition score, 
while mild cases led to the addition of a “minus symbol” 
to the score (eg, three-). The mice were scored by this sys-
tem every 12 hours, and any mouse that scored two or less 
was euthanized and the day/time recorded. The  euthanasia 
day/time data were then treated like survival data and 
 modeled using Kaplan–Meier statistics to determine the 
statistical significance of the data.
Results
Toxicity and loading of nanoparticles
The nanoparticles did not show any toxicity at concentrations 
less than 100 µg/mL iron, although some slight toxicity 
was shown at 100 µg/mL and 200 µg/mL iron (Figure 3A). 
Mo/Ma took up the nanoparticles in a manner proportional 
to the iron concentration (Figure 3B). The percentage of 
cells containing nanoparticles (defined as cells that exhibit 
increased side scatter after loading) also increased in a 
manner proportional to the iron concentration (Figure 3C). 
Based on these results, to prevent undesired toxicity while 
maximizing the amount of iron loaded, nanoparticles were 
loaded at 37.5 µg/mL iron for the in vivo experiment. To 
determine the exact amount of iron loaded in the cells for 
the in vivo experiment, when Mo/Ma were lifted for the 
in vivo experiment, excess cells were collected and iron 
content was measured using the ferrozine assay. The iron 
content of Mo/Ma injected was 2.12 ± 0.37 pg iron/cell or 
4.25 ± 0.74 µg iron/2,000,000 cells.
Tumor homing studies
To determine if Mo/Ma would home to Pan02 tumors, 
two mice bearing i.p. Pan02 tumors were injected i.p. with 
PKH26-labeled Mo/Ma. Three days after injection, the first 
mouse was euthanized. Tissue imaging showed that the 
Mo/Ma effectively homed to the tumor, but did not infil-
trate other organs, including the pancreas, spleen, liver, and 
 kidney. At 6 days, the second mouse was sacrificed and tissue 
imaging showed again that the monocyte-like cells penetrated 
tumor tissue but not healthy tissue (Figure 4).
Hematoxylin and eosin staining of serial sections 
demonstrate that the tissue to which the Mo/Ma home is highly 
disorganized, indicative of tumor tissue (Figure 5A and B). 
To further verify that the Mo/Ma were, in fact, in tumor 
tissue, five mice bearing i.p. Pan02 tumors expressing firefly 
luciferase were injected i.p. with Mo/Ma which were loaded 
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with Hoechst and magnetic nanoparticles. Four days after 
injection, the mice were euthanized. Antibody staining for 
firefly luciferase demonstrated that Mo/Ma were in tumor 
tissue (Figure 5C).
Nanoparticle heating of tumors
To verify that the cell-delivered nanoparticles could cause 
significant heating of the tumor, a subcutaneous Pan02 model 
was generated. (The subcutaneous model was used to give 
more accessible tumors for measurement purposes). The 
temperature change caused by AMF induced hyperthermia 
using the nanoparticle-loaded Mo/Ma was 4.0°C ± 0.7°C after 
15 minutes of AMF exposure, or moderate hyperthermia. As 
a comparison, the temperature change using the unloaded 
Mo/Ma was 1.0°C ± 0.5°C (Figure 6, P = 0.0056).
Mouse survival
To determine the effectiveness of the treatment, Pan02 
tumors were given i.p. to C57BL/6 mice and the mice were 
treated as described in the methods section. The euthanasia 
data were collected and modeled using Kaplan–Meier sur-
vival statistics. The data are reported as days subsequent to 
tumor injection (day zero) (Figure 7). The Kaplan–Meier test 
showed that the survival curves were significantly different 
(P , 0.005). All of the mice from the tumor control group 
were euthanized due to clinical symptoms (hereafter referred 
to as “succumbed”) by day 23. Similarly all of the Mo/Ma 
control mice succumbed by day 25, all of the nanoparticle 
control mice succumbed by day 26, and all of the AMF con-
trol mice succumbed by day 25. Modeling with Kaplan–
Meier statistics showed no significant difference between any 
of these groups. The AMF treatment mice survived substan-
tially longer, with mice lasting until 33.5 days. The survival 
of the AMF treatment group was shown to be significant 
against all control groups (P , 0.005 for all comparisons). 
The average increase in survival versus tumor control for 
the AMF treatment group was 7 days, a 31% increase in life 
expectancy post-tumor insertion.
Discussion
It has been shown here for the first time that tumor-homing 
cells specifically delivering magnetic nanoparticles for AMF 
therapy can significantly prolong the lives of mice bearing 
deep and disseminated i.p. pancreatic tumors. Paramagnetic 
core/shell iron/iron oxide magnetic nanoparticles were 
surface modified for low toxicity therapeutic use. These 
magnetic nanoparticles were loaded into Mo/Ma cells, which 
were demonstrated to be tumor homing cells. The Mo/Ma 
cells were injected i.p. into tumor-bearing mice and trafficked 
specifically to the tumor. Three days later, the mice were 
exposed to AMF, which caused the nanoparticles to generate 
heat, leading to localized hyperthermia.
It was found that the Mo/Ma homed effectively to the pan-
creatic tumors after i.p. administration. This is not surprising, 
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Figure 3 Nanoparticle loading. Monocyte/macrophage-like cells were cultured overnight in increasing concentrations of nanoparticles. The next morning cells were 
washed and assayed. (A) Toxicity of nanoparticles: cells were assayed for viability using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. (B) Loading of 
nanoparticles: cells were assayed for iron content using the ferrozine assay. (C) Percent of cells loaded: cells were assayed for increased side scatter using flow cytometry.
Note: Error bars are standard deviation. *= P , 0.05.
Abbreviations: ANOVA, analysis of variance; Fe, iron.
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Figure 4 Monocyte/macrophage-like cells (Mo/Ma) only infiltrate Pan02 tumors. PKH26-labeled Mo/Ma were injected intraperitoneally into mice bearing intraperitoneal 
Pan02 tumors. (A)–(F) Mice were euthanized 3 days after Mo/Ma injection and organs were harvested and imaged for PKH26 (Mo/Ma). Representative images are shown. 
(A) Tumor 10×; (B) tumor 40×; (C) pancreas; (D) kidney; (E) liver; and (F) lung. (G–L) Mice were euthanized 6 days after Mo/Ma injection and organs were harvested 
and imaged for PKH26 (Mo/Ma). Representative images are shown. (G) Tumor (note healthy pancreas at the top left); (H) tumor; (I) pancreas; (J) kidney; (K) liver; and 
(L) lung.
Notes: Blue = Hoechst nuclear counterstain; red = PKH26 (Mo/Ma). All scale bars are 100 µm, objective is 20× unless otherwise specified.
Pancreas A
Tumor
B C
Figure 5 Monocyte/macrophage-like cells (Mo/Ma) infiltrate Pan02 tumors. (A and B) Mo/Ma loaded with PKH26 were injected into mice bearing intraperitoneal Pan02 
tumors. Six days later mice were euthanized and tumors were harvested. (A) Hoechst nuclear counterstained section shows Mo/Ma labeled with PKH26 in tumor. 
(B) Hematoxylin and eosin staining of serial sections shows irregular morphology demonstrating that the targeted area is a tumor. Scale bars = 100 µm. (C) Mo/Ma 
labeled with Hoechst before injection were injected into mice bearing Pan02 expressing firefly luciferase tumors. Five days later mice were euthanized and tumors were 
harvested. Sections were stained with rabbit α-firefly luciferase and DyLight® 650-goat α-rabbit (Abcam, Cambridge, MA) (sections were not counterstained with Hoechst). 
Immunohistochemistry verifies that the Mo/Ma infiltrate pancreatic tumors. 
Notes: (A) Blue = Hoechst; red = PKH26 (Mo/Ma), (C) Blue = Hoechst (Mo/Ma); red = DyLight® 650 (Pan02 cells). Scale bar = 100 µm.
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because monocytes and/or macrophages are often found as 
tumor-associated cells. Rat monocytes were shown to effi-
ciently invade rat glioma spheroids in vitro and peritoneal 
macrophages specifically migrated to rat gliomas after intra-
venous or intracarotid administration.39,40 Interestingly, in this 
case, the mouse monocytes physically migrated only to the 
tumors within the peritoneal cavity, while normal tissues did 
not contain monocytes.
Classically, hyperthermia kills tumor tissue by heating 
proteins and other macromolecules to the point of denatur-
ing faster than the cell can renature them. Since the system 
demonstrated here was substantially effective with only 4 µg 
of iron injected into the mouse per treatment cycle, other 
mechanisms of action may be present. The nanoparticle 
control group demonstrates that the nanoparticles themselves 
do not have any treatment value; similarly, the AMF control 
group demonstrates that AMF treatment does not have any 
stand-alone value. The Mo/Ma control group demonstrates 
that the Mo/Ma neither increase nor decrease tumor growth. 
Thus, AMF activation of the magnetic nanoparticles is 
 primarily responsible for the effect. Low grade hyperthermia 
has been shown to recruit various immune cells, including 
dendritic cells, natural killer cells, neutrophils, and cytotoxic 
T cells.53–61 Although future studies are needed, this or another 
similar mechanism may have greatly increased the effective-
ness of the treatment and could explain why such a low dose 
of magnetic nanoparticles can effect such a large survival 
advantage. The authors are currently investigating potential 
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Figure 6 Heat generation by nanoparticle-loaded monocyte/macrophage-like cells.
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Figure 7 Duration to clinical symptoms (“survival”). 
Notes: Mice were treated and monitored as described. Mice were euthanized when 
they displayed clinical signs of cancer and the day/time was recorded (n = 5 or 6 for each 
group). P , 0.005 for alternating magnetic field treatment versus all other groups.
Abbreviations: AMF, alternating magnetic field; Mo/Ma, monocyte/macrophage-
like cells; NP, nanoparticle.
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Figure 8 Model of the demonstrated system. 
Notes: First, nanoparticles were loaded into monocyte/macrophage-like cells by inclusion in medium. The monocyte/macrophage-like cells were then injected intraperitoneally 
into mice bearing intraperitoneal Pan02 tumors and they specifically homed to the tumors. Three days after injecting the cells, the mice were exposed to an alternating 
magnetic field, which caused the nanoparticles to generate heat, leading to hyperthermia.
Abbreviations: AMF, alternating magnetic field; Fe, iron.
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mechanisms involved in mediating survival extension, and 
those results will be described in a subsequent report.
Conclusion
In this report, the development of a localized hyperthermia 
treatment using tumor-tropic Mo/Ma to deliver magnetic 
nanoparticles for AMF activation has been described 
 (Figure 8). The system described here holds potential 
for further development as a specific delivery method for 
 magnetic nanoparticle-generated localized hyperthermia for 
targeted therapy of pancreatic and other types of cancer.
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